Literature DB >> 28930982

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines.

Laura Mercatali1, Chiara Spadazzi2, Giacomo Miserocchi2, Chiara Liverani2, Alessandro De Vita2, Alberto Bongiovanni2, Federica Recine2, Dino Amadori2, Toni Ibrahim2.   

Abstract

The crosstalk between tumor cells and bone cells in the bone microenvironment is crucial to understanding the mechanism of bone metastasis formation. We developed an in vitro fully human preclinical model of a co-culture of breast cancer cells and monocytes undergoing differentiation towards osteoclasts. We optimized a model of osteoclastogenesis starting from a sample of peripheral blood collected from healthy donors. Peripheral blood mononuclear cells (PBMCs) were first separated by density gradient centrifugation, seeded at a high density and induced to differentiate by adding two growth factors (GFs): receptor activator of nuclear factor-κB ligand (RANKL) and macrophage colony-stimulating factor (MCSF). The cells were left in culture for 14 days and then fixed and analyzed by downstream analysis. In osteolytic bone metastases, one of the effects of cancer cell arrival in bone is the induction of osteoclastogenesis. We thus challenged our model with co-cultures of breast cancer cells to study the differentiation power of cancer cells with respect to GFs. A straightforward way of studying cancer cell-osteoclast interaction is to perform indirect co-cultures based on the use of conditioned medium collected from breast cancer cell cultures and mixed with fresh medium. This mixture is then used to induce osteoclast differentiation. We also optimized a method of direct co-culture in which cancer cells and monocytes undergoing differentiation share the medium and exchange secreted factors. This is a significant improvement over the original indirect co-culture method as researchers can observe the reciprocal interactions of the two cell types and perform downstream analyses for both cancer cells and osteoclasts. This method enables us to study the effect of drugs on the metastatic bone microenvironment and to seed cell lines other than those derived from breast cancer. The model can also be used to study other diseases such as osteoporosis or other bone conditions.

Entities:  

Mesh:

Year:  2017        PMID: 28930982      PMCID: PMC5752253          DOI: 10.3791/56311

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  18 in total

Review 1.  Mechanisms of bone metastasis.

Authors:  G David Roodman
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

2.  VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors.

Authors:  Xin Lu; Euphemia Mu; Yong Wei; Sabine Riethdorf; Qifeng Yang; Min Yuan; Jun Yan; Yuling Hua; Benjamin J Tiede; Xuemin Lu; Bruce G Haffty; Klaus Pantel; Joan Massagué; Yibin Kang
Journal:  Cancer Cell       Date:  2011-12-01       Impact factor: 31.743

Review 3.  Mechanisms of cancer cell metastasis to the bone: a multistep process.

Authors:  Lalit R Patel; Daniel F Camacho; Yusuke Shiozawa; Kenneth J Pienta; Russell S Taichman
Journal:  Future Oncol       Date:  2011-11       Impact factor: 3.404

4.  Tumor microenvironment complexity: emerging roles in cancer therapy.

Authors:  Melody A Swartz; Noriho Iida; Edward W Roberts; Sabina Sangaletti; Melissa H Wong; Fiona E Yull; Lisa M Coussens; Yves A DeClerck
Journal:  Cancer Res       Date:  2012-03-13       Impact factor: 12.701

5.  The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells.

Authors:  Hai Wang; Cuijuan Yu; Xia Gao; Thomas Welte; Aaron M Muscarella; Lin Tian; Hong Zhao; Zhen Zhao; Shiyu Du; Jianning Tao; Brendan Lee; Thomas F Westbrook; Stephen T C Wong; Xin Jin; Jeffrey M Rosen; C Kent Osborne; Xiang H-F Zhang
Journal:  Cancer Cell       Date:  2015-01-15       Impact factor: 31.743

6.  A multigenic program mediating breast cancer metastasis to bone.

Authors:  Yibin Kang; Peter M Siegel; Weiping Shu; Maria Drobnjak; Sanna M Kakonen; Carlos Cordón-Cardo; Theresa A Guise; Joan Massagué
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

7.  M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.

Authors:  H Glantschnig; J E Fisher; G Wesolowski; G A Rodan; A A Reszka
Journal:  Cell Death Differ       Date:  2003-10       Impact factor: 15.828

Review 8.  Bone and cancer: the osteoncology.

Authors:  Toni Ibrahim; Laura Mercatali; Dino Amadori
Journal:  Clin Cases Miner Bone Metab       Date:  2013-05

Review 9.  Breast cancer metastasis to the bone: mechanisms of bone loss.

Authors:  Yu-Chi Chen; Donna M Sosnoski; Andrea M Mastro
Journal:  Breast Cancer Res       Date:  2010-12-16       Impact factor: 6.466

10.  Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells.

Authors:  Valeria Simone; Sabino Ciavarella; Oronzo Brunetti; Annalisa Savonarola; Mauro Cives; Marco Tucci; Giuseppina Opinto; Eugenio Maiorano; Franco Silvestris
Journal:  BMC Cancer       Date:  2015-10-14       Impact factor: 4.430

View more
  2 in total

1.  Osteogenic Response of MC3T3-E1 and Raw264.7 in the 3D-Encapsulated Co-Culture Environment.

Authors:  Jungju Kim; Hao-Zhen Lyu; Chisung Jung; Kyung Mee Lee; Shi Huan Han; Jae Hyup Lee; Misun Cha
Journal:  Tissue Eng Regen Med       Date:  2021-01-07       Impact factor: 4.169

2.  BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center "Real-Life" Experience (BOHEME Study).

Authors:  Federica Recine; Alberto Bongiovanni; Flavia Foca; Laura Mercatali; Valentina Fausti; Sebastiano Calpona; Nada Riva; Alessandro De Vita; Chiara Liverani; Chiara Spadazzi; Giacomo Miserocchi; Giandomenico Di Menna; Lorena Gurrieri; Claudia Cocchi; Silvia Angela Debonis; Roberto Vespignani; Toni Ibrahim
Journal:  J Clin Med       Date:  2019-11-06       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.